The antiarrhythmic effects of a new antiarrhythmic agent, SD-3212, (-)-(S)-3,4-Dihydro-2- [5-methoxy-2-[3-[N-methyl-N-[2-[(3,4-methylene dioxy)phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1, 4-benzothiazine hydrogen fumarate, were investigated using canine models of ventricular arrhythmias, i.e. spontaneously occurring digitalis-, two-stage coronary ligation-and adrenaline-induced arrhythmias. SD-3212 suppressed adrenaline-induced arrhythmia and showed some antiarrhythmic effect on digitalis-and 48hr coronary ligation-arrhythmias.
SUMMARY
The antiarrhythmic effects of a new antiarrhythmic agent, SD-3212, (-)-(S)-3,4-Dihydro-2-[5-methoxy-2-[3-[N-methyl-N- [2-[(3,4 -methylene dioxy)phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1, 4-benzothiazine hydrogen fumarate, were investigated using canine models of ventricular arrhythmias, i.e. spontaneously occurring digitalis-, two-stage coronary ligation-and adrenaline-induced arrhythmias. SD-3212 suppressed adrenaline-induced arrhythmia and showed some antiarrhythmic effect on digitalis-and 48hr coronary ligation-arrhythmias. These results indicate that SD-3212 has antiarrhythmic effects common among class IV antiarrhythmic drugs and also has additional efficacy common among class I antiarrhythmic drugs, thus when considering the level of experimental arrhythmias it somewhat resembles propafenone. It may therefore become a clinically useful antiarrhythmic drug among typical class I or class IV antiarrhythmic drugs. thylene dioxy)phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1,4-benzothiazine hydrogen fumarate is a new synthetic antiarrhythmic drug which was reported to have antiarrhythmic effects in rat and canine models.1)-4) This compound is a stereoisomer of SD-3211, which is an investigational non-dihydropyridine type Ca2+ antagonist.5) Electrophysiological studies demonstrated that SD-3212 decreased the maximum rate of rise (Vmax) of the normally polarized action potential at a concentration range of 10-6-10-5M and decreased the action potential duration at a concentration range of 10-6-10-5M in isolated guinea pig ventricular muscle preparations, while SD-3211 only decreased the action potential duration at a con- Production of two-stage coronary ligation-induced arrhythmia Six female beagle dogs, weighing 7-11kg, were anesthetized initially with intravenous thiopental sodium, 30mg/kg, and intubated.
As reported earlier,9) the chest was opened and the two-stage coronary ligation of the left anterior descending artery (LAD) was performed under halothane anesthesia. Vol.33 No.6 Experiments were done without anesthesia 24 and 48hr after coronary ligation. The lead II ECG, atrial electrogram from implanted electrodes sutured on the left atrial appendage, and the instantaneous and mean blood pressure were recorded continuously using a telemetry system (Nihon Kohden, WEB-5000, Tokyo).
The same constant rate infusion of SD-3212 was performed for 10min using a syringe pump, and arterial blood samples were drawn from one lumen of the arterial double lumen cannula at 0, 1, 3, 5, 7, 9, 13, 15, 30 and 60min after the start of the infusion. Determination of plasma concentration of SD-3212 A sensitive and specific determination of SD-3212 in plasma was performed at Santen Pharmaceutical Co., Ltd. (Osaka, Japan) using a high performance liquid chromatographic method.12)
Statistics
One way analysis of variance (ANOVA) was used to compare treatment groups with the control group. If the ANOVA value was significant, comparisons between the control and treatment groups were performed using a one way ANOVA followed by Dunnett's t-test to localize the significant difference. A p value of less than 0.05 was considered significant. All statistics were run with Stat View 512+ statistical software (Brainpower Inc., CA, USA) on a Macintosh personal computer.
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Evaluation of the antiarrhythmic effects The severity of ventricular arrhythmia was expressed by the arrhythmic ratio: the number of ventricular ectopic beats divided by the total heart rate. The total heart rate is the number of all beats counted from the 5sec strip of ECG (i.e., the number of ventricular ectopic beats plus the number of conducted beats), and the ventricular ectopic beats were judged by the different shape of the ventricular complex from the normal QRS complex. The arrhythmic ratio before drug injection was almost 1 as shown in the control values of the figures, and there were no spontaneous improvements in these ratios. If the values after drug administration were decreased significantly from the 0 time value, the drug was judged to have antiarrhythmic effects. The antiarrhythmic plasma concentrations of drugs were determined as follows: simple linear regression was calculated between the data of plasma concentrations of a drug and the data of arrhythmic ratio when the plasma were obtained using the computer program Stat View 512+, and the plasma concentration which decreased the arrhythmic ratio to 50% of that at 0 concentration was calculated as the 50% inhibitory concentration, IC50. 
RESULTS

Digitalis
DISCUSSION
The present experiment using the 3 canine ventricular arrhythmia models confirmed previous reports that SD-3212 is effective in animal experimental arrhythmias.1)-4)
In 48hr coronary artery ligation induced ventricular arrhythmia, SD-3212, 6mg/kg/10min, showed some antiarrhythmic effect with slightly decreasing effects on the atrial rate and blood pressure, and also showed some central nervous system stimulating effect, such as vomiting. The effective antiarrhythmic plasma concentration data of SD-3212 obtained in this study may only provide a rough measure of the drug's potency as judged by the wide confidence limit, however, since there were significant correlations between the plasma concentrations and the antiarrhythmic effects, they allowed us to discuss the following. We calculated the IC50 for 48hr ar- 
